Christoph M. Ahlers

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi et al. · Journal of Clinical Oncology · 2015 · 1.2K citations · Full text

Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.

Bruce J. Dezube, Arthur B. Pardee, B Chapman et al. · PubMed · 1993 · 88 citations

Inflammation, Primary Immunodeficiency, Serum Triglycerides +14

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

Taofeek K. Owonikoko, Arif Hussain, Walter M. Stadler et al. · Cancer Chemotherapy and Pharmacology · 2015 · 87 citations

Antibody-drug Conjugate, Immunology, Antibody Screening +7

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

Julie R. Brahmer, Leora Horn, Scott Antonia et al. · Journal of Clinical Oncology · 2013 · 74 citations

Advanced Nsclc, Cancer Immunosurveillance, Medicine +15

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.

Lillian L. Siu, K. Papadopoulos, Steven R. Alberts et al. · Journal of Clinical Oncology · 2010 · 62 citations

Oral Hedgehog, Pathology, Pathway Antagonist +18